Untitled
Antidepressant Drugs
Overview
Symptoms of Depression:
- Feelings of sadness and hopelessness
- Inability to experience pleasure in usual activities
- Changes in sleep patterns and appetite
- Loss of energy
- Suicidal thoughtsSymptoms of Mania:
- Enthusiasm, anger
- Rapid thought and speech patterns
- Extreme self-confidence
- Impaired judgment
Mechanism of Antidepressant Drugs
Cause of Depression:
- Due to a deficiency of monoamines (e.g., norepinephrine and serotonin) at key sites in the brain.Cause of Mania:
- Proposed to be caused by an overproduction of neurotransmitters (norepinephrine and serotonin).Function of Antidepressant Drugs:
- Potentiate the actions of norepinephrine and/or serotonin (5-HT) in the brain, either directly or indirectly.
Limitations of Biogenic Amine Theory
Explanation Gaps:
- The time course for therapeutic response (usually several weeks) fails to align with the immediate pharmacodynamic effects of the agents.Types of Antidepressant Drugs Used in Treatment:
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)
- Atypical Antidepressants
- Tricyclic Antidepressants (TCAs)
- Monoamine Oxidase Inhibitors (MAOIs)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Characteristics:
- Inhibit serotonin reuptake with 300- to 3000-fold greater selectivity for serotonin transporter relative to norepinephrine transporter.
- Contrasts with TCAs and SNRIs that nonselectively inhibit the reuptake of norepinephrine and serotonin.Less Receptor Activity:
- Little blocking activity at muscarinic, α-adrenergic, and histaminic H1 receptors.
- Fewer common side effects than TCAs (e.g., orthostatic hypotension, sedation, dry mouth, blurred vision).Examples of SSRIs:
- Fluoxetine (prototypic drug)
- Citalopram
- Escitalopram
- Fluvoxamine
- Paroxetine
- Sertraline
SSRIs - Actions
Mechanism of Action:
- Block reuptake of serotonin, increasing concentrations of the neurotransmitter in the synaptic cleft.Onset of Effects:
- Significant improvement in mood typically takes at least 2 weeks; maximum benefit can require up to 12 weeks or longer.
- Must maintain adequate dosage for a minimum of 6 weeks before considering treatment alteration, despite adverse effects manifesting shortly after administration.
- Long-term use may lead to adaptive changes within synapses.
SSRIs - Variability
- Interindividual Variations:
- Blood levels of antidepressants can vary due to differences in drug-metabolizing enzymes and activities, affecting response rates and adverse effects.
SSRIs - Therapeutic Uses
Primary Indication:
- Depression.Other Psychiatric Disorders Responding Favorably to SSRIs:
- Obsessive-compulsive disorder
- Panic disorder
- Generalized anxiety disorder
- Bulimia nervosa (only Fluoxetine approved for bulimia)
SSRIs - Pharmacokinetics
Absorption:
- All SSRIs are well absorbed after oral administration, with little effect from food (except Sertraline, where food increases absorption).Plasma Half-Lives:
- Most SSRIs have half-lives ranging from 16 to 36 hours.
SSRIs - Pharmacokinetics (Fluoxetine)
- Unique Characteristics:
- Fluoxetine has a notably longer half-life (50 hours) and its active metabolite S-norfluoxetine averages a half-life of 10 days.
- Metabolism primarily occurs via cytochrome P450 (CYP450) dependent enzymes alongside glucuronide or sulfate conjugation.
- Fluoxetine and Paroxetine are potent CYP450 inhibitors.
SSRIs - Adverse Effects
General Adverse Effects:
- SSRIs exhibit fewer and less severe adverse effects than TCAs and MAOIs. However, potential side effects still include:
- Anxiety and agitation
- Sexual dysfunction
- Gastrointestinal (GI) upset
- Changes in weight
- Sleep disturbances (insomnia, somnolence)
- Drug–drug interactionsSerotonin Syndrome Risk:
- All SSRIs potentially induce serotonin syndrome, particularly when used with MAOIs or other serotonergic drugs.
- Symptoms may include hyperthermia, muscle rigidity, sweating, myoclonus (clonic muscle twitching), and changes in vital signs/mental status.
- Treatment: Discussed in context (not detailed).
SSRIs - Use in Specific Populations
Sedative vs. Activating SSRIs:
- Paroxetine, Citalopram, and Fluvoxamine are generally more sedating, beneficial for patients with sleep issues.
- Fluoxetine and Sertraline are more activating, suitable for fatigued patients.Caution with Children and Teenagers:
- Antidepressants can increase suicidal ideation; special caution required.
- Fluoxetine is approved for treating obsessive-compulsive disorder and childhood depression.
SSRIs - Overdose and Withdrawal
Overdose Risks:
- SSRI overdose typically does not cause cardiac arrhythmias, except Citalopram (QT prolongation risk).
- May lower seizure threshold.Black Box Warning:
- Increased risk of suicidal ideation, highlighting vigilance for children, adolescents, and young adults.Discontinuation Syndrome:
- Abrupt withdrawal may lead to discontinuation syndrome, particularly with short-half-life agents.
- Fluoxetine has lower risk due to the long half-life.
- Signs and symptoms may include headache, malaise, flu-like symptoms, agitation, irritability, nervousness, and sleep pattern changes.
Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)
Key Agents:
- Venlafaxine, Desvenlafaxine, Duloxetine.Mechanism of Action:
- Inhibit the reuptake of both serotonin and norepinephrine.
- Effective in patients unresponsive to SSRIs, particularly when chronic pain symptoms accompany depression.
SNRIs - Advantages and Discontinuation Syndrome
Receptor Activity:
- Unlike TCAs, SNRIs have little or no activity at α-adrenergic, muscarinic, or histamine receptors, resulting in fewer receptor-mediated side effects.Discontinuation Risks:
- Abrupt cessation can precipitate discontinuation syndrome.Minimal CYP450 Inhibition:
- Venlafaxine and Duloxetine exhibit minimal inhibition of CYP450 isoenzymes.
SNRIs - Venlafaxine and Desvenlafaxine
Mechanism:
- Venlafaxine inhibits serotonin reuptake and norepinephrine reuptake at medium to higher doses.
- Desvenlafaxine is the active metabolite of Venlafaxine.Common Adverse Effects:
- GI upset, sexual dysfunction, insomnia.
- High doses may increase blood pressure and heart rate.
SNRIs - Duloxetine
Mechanism:
- Inhibits serotonin and norepinephrine reuptake at all doses.Metabolism:
- Extensively metabolized in the liver to inactive metabolites; avoid in patients with liver dysfunction.Common Side Effects:
- GI issues, insomnia, somnolence, sweating, sexual dysfunction, with possible increase in blood pressure or heart rate.
Tricyclic Antidepressants (TCAs)
Key Agents:
- Imipramine (prototype), Amitriptyline, Doxepin, Clomipramine, Maprotiline, Amoxapine.Mechanism of Action:
1. Inhibition of Neurotransmitter Reuptake:
- Potent inhibitors of neuronal reuptake of norepinephrine and serotonin.
2. Blocking of Receptors:
- Block serotonergic, α-adrenergic, histaminic, and muscarinic receptors, causing many adverse effects.
- Amoxapine also blocks dopamine D2 receptors.
TCAs - Therapeutic Uses
- Indications:
- Effective for moderate to severe depression.
- Useful in panic disorder.
- Imipramine for bed-wetting in children over 6 years.
- Amitriptyline for migraine prevention and chronic pain syndromes.
- Low doses (e.g., doxepin) can induce sleep.
TCAs - Pharmacokinetics
Absorption and Distribution:
- Well absorbed orally; lipophilic nature allows wide distribution, including CNS penetration.Metabolism:
- Metabolized by hepatic microsomal system and conjugated with glucuronic acid.
- Excreted as inactive metabolites via the kidney.
TCAs - Adverse Effects
Muscarinic Effects:
- Leading to blurred vision, xerostomia, urinary retention, sinus tachycardia, constipation, and aggravation of glaucoma.Cardiac Risks:
- Affect cardiac conduction like Quinidine, potentially causing life-threatening arrhythmias in overdose cases; narrow therapeutic index.α-adrenergic Blocking Effects:
- Leading to orthostatic hypotension and reflex tachycardia.Sedation and Weight Gain:
- Sedation linked to blocking histamine H1 receptors; weight gain is common.Sexual Dysfunction:
- Lower incidence than SSRIs.Caution in Specific Conditions:
- Caution in bipolar disorder, preexisting arrhythmias, epilepsy, and benign prostatic hyperplasia.
Monoamine Oxidase Inhibitors (MAOIs)
Enzyme Function:
- MAO deaminates and inactivates excess neurotransmitters (norepinephrine, dopamine, serotonin).Mechanism of Action:
- MAOIs can irreversibly or reversibly inhibit MAO, allowing neurotransmitter accumulation in presynaptic neurons.Available Agents:
- Phenelzine, Selegiline.Limitations:
- Complicated dietary restrictions; not used widely due to adverse reactions.
MAOIs - Therapeutic Uses
- Indications:
- Unresponsive or allergic patients to TCAs and SSRIs; considered last-line treatment due to interaction risk.
MAOIs - Pharmacokinetics
Absorption:
- Well absorbed orally; hepatic metabolism dominates leading to rapid urine excretion.Regeneration of Enzyme:
- Enzyme regeneration occurs weeks after stopping; need a 2-week gap when switching from MAOIs to other antidepressants.
MAOIs - Adverse Effects
Interactions with Tyramine:
- Tyramine-containing foods (e.g., aged cheeses, cured meats) can induce hypertensive crisis due to MAO inhibition in gut, leading to catecholamine release.
- Signs of hypertensive crisis: headache, tachycardia, hypertension, arrhythmias, seizures, stroke risk.Management of Tyramine Hypertension:
- Managed with Phentolamine or Prazosin.SSRIs Co-administration Risks:
- Should not be used with MAOIs (risk of serotonin syndrome); minimum washout periods required (2 weeks, 6 weeks for fluoxetine).
Atypical Antidepressants
Group Characteristics:
- Mixed agents with varied actions at different neurotransmitter sites.Examples:
- Bupropion, Mirtazapine, Nefazodone, Trazodone, Vilazodone, Vortioxetine.
Atypical Antidepressant - Bupropion
Mechanism:
- Weak dopamine and norepinephrine reuptake inhibitor, alleviating depression symptoms.Additional Uses:
- Useful for nicotine cravings and withdrawal symptoms in smokers.Side Effects:
- Include sweating, tremors, nervousness; increased seizure risk (thresholder).
- Avoid in patients with seizure risk or eating disorders.
Atypical Antidepressant - Mirtazapine
- Mechanism:
- Enhances serotonin and norepinephrine by antagonism at presynaptic α2 and 5-HT2 receptors. - Sedating Nature:
- Markedly sedating due to potent antihistaminic properties; avoids antimuscarinic side effects of TCAs. - Weight Impact:
- Increased appetite; weight gain is frequent.
Atypical Antidepressants - Nefazodone and Trazodone
- Mechanism:
- Weak serotonin reuptake inhibitors, blocking 5-HT2 receptors post-synaptically. - Sedative Qualities:
- Both have potent histamine H1-blocking activity and can be used off-label for insomnia. - Hepatotoxic Risk:
- Nefazodone carries risk for hepatotoxicity. - Adverse Effects:
- Orthostasis and dizziness due to mild to moderate α1 receptor antagonism.
Atypical Antidepressant - Vilazodone
- Mechanism:
- Serotonin reuptake inhibitor and 5-HT1a receptor partial agonist. - Adverse Effects:
- Similar to SSRIs, including risk of discontinuation syndrome if stopped abruptly.
Serotonin-Dopamine Antagonists (SDAs)
- Patient Response Rates:
- 60% to 80% response to antidepressants; 20% to 40% experience partial or poor response to monotherapy. - Use of SDAs in Treatment:
- Atypical antipsychotics used as adjunct treatments for partial responders. - Combination Example:
- Fluoxetine with Olanzapine approved for adjunctive use in major depressive disorder (MDD).
Homework Assignments
- Can Vilazodone cause drug-drug interaction?
- Mechanism of Action (MOA) of Vortioxetine?
- Considerations for treating mania and bipolar disorder.
- Case Study Question:
- A 77-year-old man with chronic obstructive pulmonary disease using ipratropium sprays need analysis of likely effects (options listed).